Brookline Capital Management Estimates KYMR FY2029 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Equities research analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for Kymera Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann expects that the company will earn ($6.44) per share for the year. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share.

Other equities analysts also recently issued research reports about the stock. Truist Financial reiterated a “buy” rating and issued a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Leerink Partners reiterated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Friday, December 27th. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $38.00 to $57.00 in a research report on Monday, December 2nd. UBS Group reduced their price target on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Finally, Oppenheimer increased their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, September 27th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $55.38.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock opened at $40.92 on Wednesday. The stock has a market capitalization of $2.65 billion, a P/E ratio of -17.49 and a beta of 2.19. Kymera Therapeutics has a 52-week low of $25.02 and a 52-week high of $53.27. The stock’s 50-day simple moving average is $44.34 and its 200 day simple moving average is $43.94.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. The firm had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business’s revenue for the quarter was down 20.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.90) EPS.

Institutional Trading of Kymera Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its holdings in shares of Kymera Therapeutics by 212.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock worth $6,649,000 after acquiring an additional 95,547 shares during the last quarter. Franklin Resources Inc. lifted its stake in Kymera Therapeutics by 35.1% in the third quarter. Franklin Resources Inc. now owns 29,440 shares of the company’s stock worth $1,356,000 after purchasing an additional 7,647 shares during the last quarter. Wellington Management Group LLP boosted its position in Kymera Therapeutics by 7.2% during the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock valued at $218,587,000 after buying an additional 308,954 shares during the period. Quarry LP bought a new position in shares of Kymera Therapeutics during the third quarter valued at about $95,000. Finally, HighTower Advisors LLC bought a new stake in shares of Kymera Therapeutics in the 3rd quarter valued at about $494,000.

Insider Activity at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the transaction, the insider now directly owns 54,826 shares in the company, valued at approximately $2,288,985.50. This represents a 5.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 15.82% of the stock is owned by insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.